Colorado Study Finds Medical Cannabis Coverage Reduces Opioid Use

State-Funded Pilot Tracked 200 Claimants Over 18 Months

The Colorado Division of Workers' Compensation enrolled 200 injured workers in its Alternative Medicine Pilot between January 2025 and June 2026, splitting participants into a treatment group receiving cannabis coverage and a control group receiving standard care. The pilot operated under a legislative waiver enacted in 2024 that allowed the state to reimburse medical cannabis costs for workplace injuries despite federal Schedule I classification.

Participants in the treatment arm received up to $500 per month in cannabis reimbursements through state-licensed dispensaries. All claimants had chronic pain diagnoses stemming from workplace injuries and had been prescribed opioids at some point during their claims. The Division of Workers' Compensation (DOWC) tracked pain scores, opioid prescriptions, return-to-work rates, and self-reported quality-of-life metrics at 6, 12, and 18 months.

The study design required participants to maintain medical marijuana registry status and submit monthly dispensary receipts. Control-group members received standard workers' compensation medical benefits: physical therapy, pain management, and opioid prescriptions as clinically indicated.

Treatment Group Showed 34% Decline in Opioid Prescriptions

Workers whose cannabis was covered saw opioid prescription rates drop 34% over the 18-month observation period, compared to an 8% decline in the control group. The treatment group also reported a 22-point improvement on the 100-point Pain Disability Index, versus a 9-point improvement in the control arm. DOWC Director Michael Scanlon said the results suggest cannabis coverage "offers a clinically meaningful alternative" for chronic pain management in occupational injury cases.

Return-to-work rates didn't differ significantly between groups: 62% of the treatment group and 59% of the control group returned to full or modified duty by month 18. But treatment-group members who returned to work reported higher job-satisfaction scores and fewer missed workdays in months 13-18.

The study didn't track total medical costs per claimant. Scanlon acknowledged the gap in the report. "We didn't have the budget to conduct a full cost-benefit analysis," he said, noting that future research should compare cannabis reimbursement costs against opioid prescriptions, emergency-department visits, and long-term disability payments.

No Federal Funding; State General Fund Covered $1.8 Million

Colorado's General Assembly appropriated $1.8 million from the state general fund to cover pilot costs, including cannabis reimbursements, program administration, and third-party evaluation. The U.S. Department of Labor declined to provide federal workers' compensation research grants for the pilot, citing cannabis's Schedule I status and federal contracting restrictions.

The pilot's legislative authorization, House Bill 24-1424, required DOWC to submit findings to the General Assembly by August 1, 2026. The bill's sponsors—Rep. Edie Hooton (D-Boulder) and Sen. Joann Ginal (D-Fort Collins)—said the pilot was designed to inform a permanent cannabis-coverage framework if results warranted expansion.

Scanlon's report recommends the legislature consider a permanent reimbursement pathway for injured workers with qualifying conditions. It doesn't propose a specific reimbursement cap or dispensary-network structure.

Participants Self-Selected; No Randomization

The pilot relied on voluntary enrollment rather than random assignment, a design limitation that may skew results toward participants already inclined to use cannabis. All 200 participants were existing medical marijuana registry cardholders at the time of enrollment, meaning they'd already obtained physician certifications and paid state registry fees.

The study's methodology section acknowledges this self-selection bias. "Participants who opted into the treatment arm may have had stronger preferences for cannabis over opioids, which could account for some of the observed differences," the report states. Control-group participants consisted of registry cardholders who declined cannabis coverage and continued standard care.

DOWC didn't conduct urine or blood testing to verify cannabis use or measure THC levels. Compliance was tracked through dispensary receipts and self-reported consumption logs. Eighteen treatment-group participants (18%) dropped out before the 18-month endpoint, compared to 12 control-group dropouts (12%).

Implications for Other State Workers' Comp Systems

Colorado is one of three states—alongside New Mexico and New Jersey—that have authorized medical cannabis reimbursement through workers' compensation systems, though implementation varies widely. New Mexico's workers' compensation statute allows cannabis coverage if an authorized healthcare provider certifies it as medically necessary and the employer doesn't object. New Jersey's statute permits coverage but leaves reimbursement rates to case-by-case negotiation between insurers and claimants.

Colorado's pilot offers the first controlled comparison of health outcomes under cannabis coverage versus standard care, providing a data foundation that other states have lacked when debating similar policies.

The National Council on Compensation Insurance (NCCI), which develops advisory loss costs for most state workers' comp systems, hasn't issued guidance on cannabis-related claims. NCCI spokesperson Laura Backus said the organization is "monitoring state-level developments" but hasn't modeled cannabis coverage into its actuarial frameworks.

For full background on state-level cannabis reimbursement policies, see the CannIntel topic hub on workers' compensation and medical cannabis.

Federal Schedule I Status Remains Barrier to Multi-State Research

The Drug Enforcement Administration's continued classification of cannabis as Schedule I prevents federal agencies from funding workers' compensation research involving direct cannabis provision or reimbursement. The National Institute on Drug Abuse (NIDA) and the National Institutes of Health (NIH) can fund observational studies of cannabis use but can't fund interventional trials that provide cannabis to participants.

Colorado's pilot circumvented this restriction by using state-only funding and operating under state law. The study's principal investigator, Dr. Amanda Reiman of the Colorado School of Public Health, said federal rescheduling to Schedule III or lower would enable multi-state comparative-effectiveness trials. "Right now, every state is designing its own experiment in isolation," Reiman said.

The Biden administration's proposed rule to reschedule cannabis to Schedule III remains under review at the Office of Management and Budget, with no final action expected before the 2026 election. If finalized, Schedule III status would ease some research restrictions but wouldn't automatically authorize workers' compensation coverage, which is governed by state statute.

What to Watch: Legislative Action by December 2026

The Colorado General Assembly will reconvene in January 2027. Rep. Hooton said she plans to introduce legislation establishing a permanent cannabis-reimbursement pathway for workers' compensation claimants with chronic pain, though she hasn't finalized a bill draft. Insurers and employer groups haven't taken public positions on permanent coverage.

DOWC's final report includes a recommendation that the legislature cap monthly reimbursements at $400 and limit coverage to claimants who've completed at least six months of standard pain-management treatment. The next signal: whether the 2027 session produces a floor vote on permanent coverage or punts the question to another pilot cycle.